Skip to content
The Policy VaultThe Policy Vault

JesduvroqMedical Mutual

Anemia in a patient with chronic kidney disease who is on dialysis

Initial criteria

  • Patient is age ≥ 18 years; AND
  • Patient has been receiving dialysis for at least 4 consecutive months; AND
  • Patient meets ONE of the following (a or b):
  • a) Patient meets BOTH of the following (1 and 2):
  • (1) Patient is currently receiving an erythropoiesis-stimulating agent AND transitioning to Jesduvroq; AND
  • (2) Patient has a hemoglobin level ≤ 12.0 g/dL; OR
  • b) Patient meets BOTH of the following (1 and 2):
  • (1) Patient is NOT currently receiving an erythropoiesis-stimulating agent; AND
  • (2) Patient has a baseline hemoglobin level < 11 g/dL; AND
  • Patient meets ONE of the following (a or b):
  • a) Patient is currently receiving iron therapy; OR
  • b) According to the prescriber, patient has adequate iron stores; AND
  • The medication is prescribed by or in consultation with a nephrologist

Reauthorization criteria

  • Patient is age ≥ 18 years; AND
  • Patient has been receiving dialysis for at least 4 consecutive months; AND
  • Patient has a hemoglobin level ≤ 12.0 g/dL; AND
  • Patient meets ONE of the following (a or b):
  • a) Patient is currently receiving iron therapy; OR
  • b) According to the prescriber, patient has adequate iron stores; AND
  • The medication is prescribed by or in consultation with a nephrologist; AND
  • According to the prescriber, patient has experienced a response to therapy (e.g., increase or stabilization in hemoglobin levels, or reduction/absence in red blood cell transfusions)

Approval duration

Initial: 6 months; Reauth: 1 year